Randomised controlled double-blind non-inferiority trial of two antivenoms for Saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria

PLoS Neglected Tropical Diseases

Volumn 4, Issue 7, 2010, Pages

  Abubakar, Isa S ^a   Abubakar, Saidu B ^b   Habib, Abdulrazaq G ^a   Nasidi, Abdulsalam ^c   Durfa, Nandul ^c   Yusuf, Peter O ^d   Larnyang, Solomon ^a   Garnvwa, John ^e   Sokomba, Elijah ^f   Salako, Lateef ^g   Theakston, R David G ^e   Juszczak, Ed ^h   Alder, Nicola ^h   Warrell, David A ⁱ  

^a BAYERO UNIVERSITY   (Nigeria)

^b General Hospital Kaltungo   (Nigeria)

^c Federal Ministry of Health   (Nigeria)

^d AHMADU BELLO UNIVERSITY   (Nigeria)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF JOS   (Nigeria)

^g UNIVERSITY OF IBADAN   (Nigeria)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE PHOSPHATE; EQUINE VENOM ANTISERUM; FLUCLOXACILLIN; GENTAMICIN; METRONIDAZOLE; OCTANOIC ACID; OVINE VENOM ANTISERUM; PARACETAMOL; TETANUS TOXOID; UNCLASSIFIED DRUG; VENOM ANTISERUM; VIPER VENOM;

ADOLESCENT; ADULT; ANAPHYLAXIS; ARTICLE; BITIS ARIETANS VENOM; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; BRONCHOSPASM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; ECHIS OCELLATUS; ENVENOMATION; EPISTAXIS; FEMALE; GASTROINTESTINAL SYMPTOM; GINGIVA BLEEDING; HEMATEMESIS; HEMATURIA; HEMOPTYSIS; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MELENA; NAJA NIGRICOLLIS; NIGERIA; OUTCOME ASSESSMENT; PAIN; PRESCHOOL CHILD; PROBABILITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SERUM SICKNESS; SKIN NECROSIS; SNAKE; SNAKEBITE; URTICARIA; VOMITING; ANIMAL; COMPARATIVE STUDY; DRUG ANTAGONISM; INTOXICATION; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMALS; ANTIVENINS; BLOOD COAGULATION TESTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NIGERIA; POISONING; TREATMENT OUTCOME; VIPER VENOMS; VIPERIDAE; YOUNG ADULT;

EID: 77957923428     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000767     Document Type: Article

References (39)

1. Warrell DA, Arnett C (1976) The importance of bites by the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Quart J Med 46: 33-62.
2. Trape JF, Pison G, Guyavarch E, Mane Y (2001) High mortality from snakebite in south-eastern Senegal. Trans R Soc Trop Med Hyg 95: 420-423.
3. Visser LE, Kyei-Faried S, Belcher DW, Geelhoed DW, van Leeuwen JS, et al. (2008) Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans R Soc Trop Med Hyg 102: 445-450.
4. Chippaux JP, Lang J, Amadi-Eddine S, Fagot P, Le Mener V (1999) Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. Am J Trop Med Hyg 61: 1017-1018.
5. Chippaux JP, Massougbodji A, Stock RP, Alagon A, Investigators of African Antivipmyn in Benin (2007) Clinical trial of an F(ab')2 polyvalent equine antivenom for African snake bites in Benin. Am J Trop Med Hyg 77: 538-546.
6. Warrell DA, Davidson NMcD, Greenwood BM, Ormerod LD, Pope HM, et al. (1977) Poisoning by bites of the saw-scaled or carpet viper (Echis carinatus) in Nigeria. Quart J Med 46: 33-62.
7. Sano-Martins IS, Fan HW, Castro SCB, Tomy SC, França FO, et al. (1994) Reliability of the simple 20 minute whole blood clotting test (WBCT20) as an indicator of low plasma. Toxicon 32: 1045-1050.
8. Meyer WP, Habib HG, Onayade AA, Yakubu A, Smith DC, et al. (1997) First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: Randomised comparative trial with Institute Pasteur serum (Ipser) Africa antivenom. Am J Trop Med Hyg 56: 291-300.
9. Warrell DA, Davidson NM, Ormerod LD, Pope HM, Watkins BJ, et al. (1974) Bites by the saw-scaled or carpet viper (Echis carinatus): a trial of two specific antivenoms. BMJ 4: 437-440.
10. Warrell DA, Pope HM, Prentice CR (1976) Disseminated intravascular coagulation caused by the carpet viper (Echis carinatus): trial of heparin. Br J Haematol 33: 335-342.
11. Warrell DA, Warrell MJ, Edgar W, Prentice CRM, Mathison J, et al. (1980) Comparison of Pasteur and Behringwerke antivenoms in envenoming by the carpet viper (Echis carinatus). BMJ 280: 607-609.
12. Chippaux JP, Massougbodji A, Stock RP, Alagon A, Investigators of African Antivipmyn in Benin (2007) Investigators of African Antivipmyn in Benin Clinical trial of an F(ab')2 polyvalent equine antivenom for African snake bites in Benin. Am J Trop Med Hyg 77: 538-546.
13. Myint-Lwin, Phillips RE, Tun-Pe, Warrell DA, Tin-Nu SWE, et al. (1985) Bites by Russell's viper (Vipera russelli siamensis) in Burma: haemostatic, vascular, and renal disturbances and response to treatment. Lancet 2: 1259-1264.
14. Warrell DA, Looareesuwan S, Theakston RD, Phillips RE, Chanthavanich P, et al. (1986) Randomized comparative trial of three monospecific antivenoms for bites by the Malayan pit viper (Calloselasma rhodostoma) in southern Thailand: clinical and laboratory correlations. Am J Trop Med Hyg 35: 1235-1247.
15. Cardoso JL, Fan HW, França FOS, Jorge MT, Leite RP, et al. (1993) Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in São Paulo, Brazil. Q J Med 86: 315-325.
16. Smalligan R, Cole J, Brito N, Laing GD, Mertz BL, et al. (2004) Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms. BMJ 329: 1129-1133.
17. Otero R, León G, Gutiérrez JM, Rojas G, Toro MF, et al. (2006) Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg 100: 1173-1182.
18. Nasidi A (2010) Snakebite a serious public health problem for Nigeria and Africa http://www.who.int/bloodproducts/animal_sera/A.Nasidi.pdf (accessed 2010).
19. Pugh RN, Theakston RD (1980) Incidence and mortality on snake bite in savanna Nigeria. Lancet 2: 1181-1183.
20. Theakston RDG, Warrell DA (2000) Crisis in antivenom supply for Africa. Lancet 356: 2104.
21. Lalloo DG, Theakston RDG, Warrell DA (2002) Reply to letter by Horton, R. entitled 'Ghana: defining the African challenge'. Lancet 359: 1527.
22. Theakston RD, Warrell DA, Griffiths E (2003) Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 41: 541-557.
23. Stock RP, Massougbodji A, Alagón A, Chippaux JP (2007) Bringing antivenoms to Sub-Saharan Africa. Nat Biotechnol 25: 173-177.
24. Warrell DA (2008) Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product- 'whats' in a name?' Trans R Soc Trop Med Hyg 102: 397-399.
25. Warrell DA, Williams D (2009) Response to comment on: Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. Trans R Soc Trop Med Hyg doi:10.1016/ j.trstmh.2009.06.004.
26. WHO (2007) Rabies and Envenomings a Neglected Public Health Issue. Report of a Consultative Meeting WHO, Geneva 10 January.
27. Williams D, Gutiérrez JM, Harrison R, Warrell DA, White J, et al. (2010) Viewpoint: An Antidote for Snake Bite: The Global Snake Bite Initiative. Lancet 375: 89-91.
28. WHO (2010) Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Expert Committee on Biological Standardization, World Health Organization, Geneva.
29. Laing GD, Lee L, Smith DC, Landon J, Theakston RDG (1995) Experimental assessment of a new, low-cost antivenom for treatment of carpet viper (Echis ocellatus) envenoming. Toxicon 33: 307-313.
30. Boyer LV, Seifert SA, Clark RF, McNally JT, Williams SR, et al. (1999) Recurrent and persistent coagulopathy following pit viper envenomation. Arch Intern Med 159: 706-710.
31. Ho M, Warrell DA, Looareesuwan S, Phillips RE, Chanthavanich P, et al. (1986) Clinical significance of venom antigen levels in patients envenomed by the Malayan pit viper (Calloselasma rhodostoma). Am J Trop Med Hyg 35: 579-587.
32. Rojas G, Jimenez JM, Gutiérrez JM (1994) Caprylic acid fractionation of hyperimmune horse plasma. Description of a simple procedure for antivenom production. Toxicon 32: 351-363.
33. Gutiérrez JM, Rojas E, Quesada L, Léon G, Núñez J, et al. (2005) Pan-African polyspecific antivenom produced by caprylic acid purification of horse IgG: an alternative to the antivenom crisis in Africa. Trans R Soc Trop Med Hyg 99: 468-475.
34. Segura A, Villalta M, Herrera M, León G, Harrison R, et al. (2010) Preclinical assessment of the efficacy of a new antivenom (EchiTAb-Plus-ICP) for the treatment of viper envenoming in sub-Saharan Africa. Toxicon 55: 369-374.
35. Abubakar SB, Abubakar IS, Habib AG, Nasidi A, Durfa N, et al. (2009) Preclinical and preliminary dose-finding and safety studies to identify candidate antivenoms for treatment of envenoming by saw-scaled or carpet vipers (Echis ocellatus) in northern Nigeria. Toxicon 55: 719-723.
36. Ho M, Silamut K, White NJ, Karbwang J, Looareesuwan S, et al. (1990) Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand. Am J Trop Med Hyg 42: 260-266.
37. Ramos-Cerrillo B, de Roodt AR, Chippaux JP, Olguín L, Casasola A, et al. (2008) Characterization of a new polyvalent antivenom (Antivipmyn Africa) against African vipers and elapids. Toxicon 52: 881-888.
38. Massougbodgi A, Chippaux J-P (2009) Preliminary dose-finding study with a new F(ab')2 antivenom. Abstract 83-1, XVI World Congress of the International Society on Toxinology, Recife, Pernambuco, Brazil March 15-20.
39. Habib AG, Nasidi A, Alder N, Juszczak E, Theakston RDG, et al. (2010) The 3+3 dose escalation design is appropriate for preliminary clinical assessment of efficacy and safety of candidate antivenoms. Toxicon 55: 1410-1411.